<code id='3357D6266B'></code><style id='3357D6266B'></style>
    • <acronym id='3357D6266B'></acronym>
      <center id='3357D6266B'><center id='3357D6266B'><tfoot id='3357D6266B'></tfoot></center><abbr id='3357D6266B'><dir id='3357D6266B'><tfoot id='3357D6266B'></tfoot><noframes id='3357D6266B'>

    • <optgroup id='3357D6266B'><strike id='3357D6266B'><sup id='3357D6266B'></sup></strike><code id='3357D6266B'></code></optgroup>
        1. <b id='3357D6266B'><label id='3357D6266B'><select id='3357D6266B'><dt id='3357D6266B'><span id='3357D6266B'></span></dt></select></label></b><u id='3357D6266B'></u>
          <i id='3357D6266B'><strike id='3357D6266B'><tt id='3357D6266B'><pre id='3357D6266B'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge